project id: TCGA-PRAD; case submitter id: TCGA-ZG-A8QX; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.5; rna integrity number: 7.6; age at index: 56; days to birth: -20683; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1957; age at diagnosis: 20683; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 442.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 167; initial weight: 210.0; sample id: b320bc49-257a-4121-a226-1bf5d19f0edc; sample submitter id: TCGA-ZG-A8QX-01A; portion id: 004af8cb-836b-40b0-add6-2db47b7a5bf5; portion submitter id: TCGA-ZG-A8QX-01A-11; slide id: 65dd11e4-1def-458d-9e44-c29c2521949d; slide submitter id: TCGA-ZG-A8QX-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 80.0; percent tumor nuclei: 90.0; section location: TOP;